Corden Pharma - A Full-Service CDMO’s Post

> CordenPharma Chenôve (FR) completes €35m Phase 2 investment with the inauguration of new small molecule and lipid development, manufacturing and purification facilities. On Monday 2 September, CordenPharma Chenôve Managing Director James Leresche, the site Leadership team (Virginie HILAND, Jocelyne breval, Beatrice LUCAS, André SEMERIE, Sebastien Rose, Charles Leslie DEGILA) and Project Manager Cyril BECAT were joined by CordenPharma CEO Dr. Michael Quirmbach, COO Dr. Lee Newton, Chief Quality & Compliance Officer William Cashin, Chief Commercial Officer Dr. Stephan Haitz and CFO Gary Hughes to inaugurate the completion of the expansion assets for lipids and small molecules at the site. The day began with a breakfast for all employees, followed by executive leadership remarks and an inauguration ceremony in the new synthesis building with key team players on the project. The expansion completed phase 2 of an overall investment started in 2021 after the French Government launched a “Capacity Building” program called AMI (Appel à Manifestation d’Intérêt) to support and boost the industrialization of health products in France.   Phase 1, completed in 2022, included the renovation of an R&D laboratory and the addition of several analytical instruments, a GMP mid-scale purification unit, and a newly-hired, focused team of experts. Phase 2 includes the design and construction of a larger GMP manufacturing facility at CordenPharma Chenôve, with a manufacturing concept which increases production capacity to provide customers with multi metric tons of small molecules and lipids using modern chemical reaction, isolation and purification equipment and, in particular, sustainable and innovative Supercritical Fluid Chromatography (SFC) technology, thus reducing supply chain environmental footprint. New expansion features include 6 m3 reactors, agitated filter dryers and centrifuges, the installation of 76 mm and 220 mm SFC technology, and a skid for hydride chemistry, as well as a new warehouse (-20°, 5°C and +20 °C), and storage tank farm extensions for improved storage conditions. The additions not only increase capacity but allow for future pipeline growth. Michael Quirmbach comments, “The completion of this strategic investment will augment our robust lipid and small molecule platforms to support innovators with the complex modalities and sustainable technologies they need for the development and commercialization of LNP-based xRNA and other small molecule therapeutics.” #CordenPharma #francepharma #greenchemistry #purification #lipids #lnps #mrna #pharmamanufacturing #sfc #smallmolecules #pharmaceuticals

Attending CPHI Milan 2024? Visit us at hall 24, booth 24C2 to discover our unique end-to-end CDMO service offerings across six technology platforms to support your complex pharmaceutical modalities and ultimately, the well-being of your patients. Request a meeting with our team by submitting this form: https://lnkd.in/ev38Mey6 Learn more about our: - GLP-1 Peptide Expansion in Europe & the US - LNP GMP Manufacturing Capabilities - Large-scale Terminal & Aseptic Injectable Manufacturing - Specialized Custom & Standard Catalog Lipid Production, including LNP Starter Kits for effective mRNA Formulation - Broad Oral Solid Dose Capacities, including Bioavailability Enhancement, and Oral Peptides - Extensive Small Molecule Capacities We hope to see you soon in Milan! #cordenpharma #cphi #cphimilan #cdmo #pharma #pharmaindustry #pharmaceuticals #drugdevelopment #peptides #glp1 #lipids #lnps #osd #injectables #mRNA

> Join our Lipid Development Team at the 8th Intl Symposium on Phospholipids in Pharmaceutical Research, 9-11 September 2024, organized by the Phospholipid Research Center Heidelberg in Germany. Click for more info: https://lnkd.in/emZgWsuf Visit our Posters: “Generation of highly pure lipids” by Uwe Albrecht, Markus Baumann, Patrick Gass, Zuzana Handlova, Felizitas Kirner, Alexander Klaiber, Markus Juza, Nicolas Spinner, Michael Vogel “Varying the lipid composition when designing RNA-loaded LNPs might show greater cellular and in vivo results which are also dependent on quality profiles of lipids”  by Serra Gürcan, Adrien Badier, Guy Vollmer Take notice of our robust lipid development platform with: - Advanced synthetic methodologies for lipid synthesis, enabling access to a broad structural landscape. - Sophisticated purification technologies such as lipid crystallization, and green chromatographic technologies such as SFC (Supercritical Fluid Chromatography). - Leading analytical technologies allowing controlled synthesis of lipids and precise quality determination of our lipid products. Our innovative technologies and synthesis processes are routinely employed in the generation of highly pure lipids such as: - Cationic / ionizable lipids that interact with the negatively charged nucleic acids to encapsulate and enhance cellular internalization. - PEGylated lipids / PEG free polymer as an alternative system for therapeutic applications (CordenPharma’s IP for reduced immunogenicity purpose) that help increase stability and half-life and prevent aggregation. - Phospholipids (helper lipids) that form the surface membrane of LNPs. - Sterols that enhance membrane fluidity, including BotaniChol® (CordenPharma’s non-animal origin cholesterol), beta-sitosterol, stigmasterol, and sitostanol. Discover our LNP Starter Kits, composed of essential lipid components needed to create and optimize your LNPs for effective targeting of mRNA delivery and gene therapy. CordenPharma Standard Lipid Catalog: https://lnkd.in/eUErHs3d CordenPharma LNP Starter Kits: https://lnkd.in/eTK2ZSPj #CordenPharma #cdmo #drugdevelopment #pharmaceuticals #lipids #research #mRNA #sustainability #genetherapy #technology #greenchemistry #purification #crystallization #lnps #phospholipids  

Today, as we celebrate World Charity Day, we couldn’t think of a better way to honor it than by sharing our concrete actions within our community. At CordenPharma, our commitment to giving back to society is part of who we are. This summer, our dedication had special meaning as we combined our summer events with a specific focus: contributing to a healthcare organization with a symbolic donation for each of our employees We proudly supported several healthcare organizations ( LILT SEZIONE BERGAMO Epilepsie-France, Community Foundation Boulder County, Schweizerische Morbus Crohn / Colitis Ulcerosa Vereinigung, Hilfe für krebskranke Kinder Frankfurt e. V.,  LIGUE FRIBOURGEOISE CONTRE LE CANCER, Kinderspitex Nordwestschweiz, Seltene Krankheiten – Förderverein für Kinder mit seltenen Krankheiten Schweiz, Maria Letizia Verga Centre , Portuguese Inflammatory Disease Association of the intestine, CLARA - Ecumenical Children's and Youth Hospice Service- Mannheim), selected by our sites, by making donations that target a variety of diseases. These contributions are closely aligned with our business focus areas and reflect our commitment to improving health outcomes worldwide. By integrating these charitable actions into our summer events, we brought our team together with a shared purpose—making a real difference in the lives of others. Our summer initiative was more than just a series of events; it was a reflection of our values in action. Through our donations, we’ve not only strengthened our ties to the community but also enhanced our team spirit and working culture. We are very proud of what we’ve accomplished together as One CordenPharma. When we come together with passion and purpose, we can achieve incredible things. Thanks to all our employees for being part of this journey! #cordenpharma #CDMO #worldcharityday #corporateresponsibility #givebacktosociety

We would like to welcome, Christian Merz, Managing Director, CordenPharma Plankstadt, to the CordenPharma team! #cordenpharma #cdmo #leadership #drugproducts #pharmamanufacturing #pharmaceuticals 

Attending the PDA/FDA Joint Regulatory Conference 2024 in Washington?  Visit us at booth 310! Our team will be there to discuss our bespoke end-to-end solutions, covering all stages from drug development to commercialization. #cordenpharma #pdafda #cdmo #pharma #pharmaceuticals #pharmaindustry #drugdevelopment

We would like to welcome Michael Landau, Managing Director, CordenPharma Colorado, to the CordenPharma team! #cordenpharma #colorado #cdmo #leadership #apis #pharmaceuticals #pharmamanufacturing #peptides #hpapis

Visit us at ChemOutsourcing from September 3rd to 6th! Our team will be at booth #45, ready to answer all your questions about how we can support your drug development lifecycle at all stages, from sourcing of raw materials to secure your supply chain, through preclinical & commercial development and manufacturing of GMP starting materials, APIs, Lipid excipients, Lipid NanoParticles (LNPs), finished dosage drug products, Packaging and final distribution. #cordenpharma #chemoutsourcing2024 #cdmo #pharma #pharmaceuticals #drugdevelopment #drugproduct #apis

Join us at the Peptides Therapeutics Forum in Basel on August 22nd and 23rd - booth number 1 Don't miss out our poster presentation titled 'Flow – SPPS towards greener and more efficient peptide manufacturing' by Senior Scientist Oliver Kracker. #cordenpharma #cdmo #peptides #pharmaceuticals #pharmaindustry #drugdevelopment